THC

THC

USD

Tenet Healthcare Corporation Common Stock

$148.030+2.530 (1.739%)

Reaalajas hind

Healthcare
Medical Care Facilities
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$145.500

Kõrge

$149.570

Madal

$145.270

Maht

0.21M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

13.7B

Tööstusharu

Medical Care Facilities

Riik

United States

Kauplemisstatistika

Keskmine maht

1.75M

Börs

NYQ

Valuuta

USD

52 nädala vahemik

Madal $109.82Praegune $148.030Kõrge $171.2

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 2. mai 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

THC: Tenet Healthcare Corporation Common Stock - What's Driving the Recent Action and What Might Be Next?

Stock Symbol: THC Generate Date: 2025-05-02 23:25:34

Alright, let's break down what's been going on with Tenet Healthcare stock lately. We've got some fresh news, a look at how the price has moved, and even a peek at what an AI model thinks is coming.

Recent News Buzz: Mostly Good Vibes

The news flow around THC has been pretty upbeat in the last few days of April. The biggest splash came from the company itself, reporting some seriously strong numbers for the first quarter of 2025. We're talking net income hitting $406 million, which translates to $4.27 per share. Even better, their adjusted earnings per share jumped a solid 35.4% compared to the same time last year. That's a clear sign the business is performing well right now.

Following those good earnings, a few big investment banks chimed in. Barclays, RBC Capital, and UBS all kept their positive ratings on the stock ("Overweight," "Outperform," and "Buy," respectively). Not only that, but they also raised their price targets. UBS is the most bullish, bumping their target all the way up to $230. RBC went to $189, and Barclays to $171. This tells us that analysts who follow the company closely are feeling more confident about its future value after seeing the latest results.

Now, it wasn't all sunshine. A couple of weeks earlier, back in mid-April, Baird actually downgraded the stock and lowered their price target. But looking at the more recent news, especially the earnings report and the subsequent analyst upgrades, the overall sentiment has definitely swung positive.

Price Check: A Big Jump Lately

Looking at the stock's journey over the last month or so, it's been a bit of a rollercoaster. The price dipped quite a bit through March and into early April, hitting a low around $109.82 on April 21st. Ouch.

But then, something shifted. Right around the time of that strong earnings report (April 29th), the stock saw a significant pop. It jumped from around $128 to over $138 in one day, and it's kept climbing since. The last price we have data for is $148.03 on May 2nd. So, after a rough patch, the stock has seen a sharp move upwards, likely fueled by that positive news.

What about the immediate future? An AI prediction model is forecasting continued upward movement, suggesting a gain of 0.74% today, 2.57% tomorrow, and 4.09% the day after. That aligns with the recent positive momentum.

Putting It Together: Outlook & Ideas

Based on the combination of strong earnings, multiple analysts raising their price targets, the stock's recent upward surge, and the AI's positive short-term forecast, the near-term picture for THC looks quite favorable. It seems the market is reacting positively to the company's performance and the increased confidence from analysts.

What might this suggest? The current situation seems to lean towards favoring potential buyers or those looking to add to their position. The momentum is clearly positive right now.

Potential Entry Consideration: The stock has already made a big move. The AI model suggested potential entry points slightly below the current price, around $146.61 or $147.57. While the price is just above that now, if you're considering getting in, you might look at the current level or perhaps wait for any minor dip back towards that $147-$148 area. The recent price action shows strong buying interest around these levels following the earnings news.

Potential Exit/Stop-Loss Consideration: Managing risk is always key. The AI model gave a very short-term take profit idea at $148.19, which is basically right where the stock is now – maybe useful for super quick trades, but the analyst targets are much higher. Those higher targets ($171, $189, $230) could be seen as potential upside goals over a longer timeframe if the positive trend continues. For a stop-loss, the AI suggested $130.75. This level is well below the recent jump and could serve as a point to reconsider if the positive momentum completely reverses. Setting a stop-loss below the low of the big jump day (around $126.75 on April 29th) could also be a strategy to protect against a breakdown of the recent rally.

Company Context

Just a quick reminder about Tenet Healthcare: they're a big player in the healthcare services world, running hospitals and outpatient centers. So, when they report strong earnings like they just did, it tells us their core business of providing medical care is doing well. While they do carry a good amount of debt (something to be aware of), their recent profitability and return on equity look solid. The positive news and analyst views are directly tied to how well they're executing in their industry.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research or consult with a qualified financial advisor before making any investment decisions.

Seotud uudised

Analyst Upgrades

Barclays Maintains Overweight on Tenet Healthcare, Raises Price Target to $171

Barclays analyst Andrew Mok maintains Tenet Healthcare with a Overweight and raises the price target from $161 to $171.

Vaata rohkem
Barclays Maintains Overweight on Tenet Healthcare, Raises Price Target to $171
Analyst Upgrades

RBC Capital Maintains Outperform on Tenet Healthcare, Raises Price Target to $189

RBC Capital analyst Ben Hendrix maintains Tenet Healthcare with a Outperform and raises the price target from $183 to $189.

Vaata rohkem
RBC Capital Maintains Outperform on Tenet Healthcare, Raises Price Target to $189
Analyst Upgrades

UBS Maintains Buy on Tenet Healthcare, Raises Price Target to $230

UBS analyst A.J. Rice maintains Tenet Healthcare with a Buy and raises the price target from $217 to $230.

Vaata rohkem
UBS Maintains Buy on Tenet Healthcare, Raises Price Target to $230
BusinessWire

Tenet Reports Strong First Quarter 2025 Results

Net income available to common shareholders in first quarter 2025 was $406 million, or $4.27 per diluted share Adjusted diluted earnings per share1 increased 35.4% to $4.36 in first quarter 2025 compared to $3.22 in

Vaata rohkem
Tenet Reports Strong First Quarter 2025 Results
Analyst Upgrades

Baird Downgrades Tenet Healthcare to Neutral, Lowers Price Target to $137

Baird analyst Michael Ha downgrades Tenet Healthcare from Outperform to Neutral and lowers the price target from $153 to $137.

Vaata rohkem
Baird Downgrades Tenet Healthcare to Neutral, Lowers Price Target to $137

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 4. mai 2025, 01:55

LangevNeutraalneTõusev

72.2% Kindlus

Risk ja kauplemine

Riskitase3/5
Keskmine risk
Sobib
VäärtusKonservatiivneAgressiivne
Kauplemisjuhend

Sisenemispunkt

$148.45

Võta kasum

$158.46

Peata kahjum

$133.24

Põhitegurid

DMI näitab langustrendi (ADX:20.5, +DI:5.5, -DI:6.1), mis viitab ettevaatlikkusele
Praegune hind on tugitasemele ($148.03) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 7.1x keskmisest (17,556), mis viitab äärmiselt tugevale ostusurvele
MACD -0.1608 on signaalijoone -0.2017 kohal, mis viitab tõusvale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.